Eupraxia Pharmaceuticals Inc. (EPRX) News
Follow Eupraxia Pharmaceuticals Inc. (EPRX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Eupraxia Pharmaceuticals Inc. (EPRX) Reports 52-Week Data Showing 64% Clinical Remission
Eupraxia reported updated Phase 1b/2a RESOLVE data for EP-104GI in EoE, with 64% of patients in clinical remission over 52 weeks in higher-dose cohorts and histologic improvements observed; no treatment-related SAEs repo
NEWS | Sep 30, 2026, 12:01 PM UTC
L
Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
VANCOUVER, British Columbia, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) NASDAQ:EPRX TSX:EPRX, a clinical-stage biotechnology company leveraging its proprietary Diffusph
NEWS | Sep 30, 2026, 12:01 PM UTC
L
Eupraxia Pharmaceuticals Initiated at Outperform by Wedbush
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 12:49 PM UTC
L
EPRX: Once-yearly dosing and strong safety position the therapy for leadership in EoE and beyond
EoE is a rapidly growing market with significant unmet need, and the therapy’s once-yearly, physician-administered dosing offers strong compliance and commercial advantages. Detailed interim phase II-B data in December w
NEWS | Sep 14, 2026, 07:36 PM UTC
L
EPRX: Once-yearly therapy for EoE targets compliance and durability, with pivotal data due in December
EoE is a rapidly growing market with significant unmet needs, and a once-yearly, physician-administered therapy is positioned to address compliance and durability challenges. Interim Phase IIb data in December will provi
NEWS | Sep 14, 2026, 07:04 PM UTC
L
Eupraxia Pharmaceuticals completes Nasdaq Global Select Market transfer
Eupraxia Pharmaceuticals has completed its transfer to the Nasdaq Global Select Market and announced it will participate in upcoming investor conferences.
EQUITY | Sep 08, 2026, 12:07 PM UTC
L
Eupraxia Pharmaceuticals completes Nasdaq Global Select Market transfer
Eupraxia Pharmaceuticals (EPRX) completes its transfer to the Nasdaq Global Select Market and will participate in upcoming investor conferences.
EQUITY | Sep 08, 2026, 12:00 PM UTC
L
Eupraxia Pharmaceuticals reports new RESOLVE Phase 1b/2a symptom response data
Eupraxia Pharmaceuticals (EPRX) reports symptom response data from its ongoing Phase 1b/2a RESOLVE trial, including new data on odynophagia in eosinophilic esophagitis patients.
EQUITY | Aug 13, 2026, 12:10 PM UTC
L
Eupraxia Pharmaceuticals Q2 EPS In Line
Eupraxia Pharmaceuticals reports Q2 EPS of $(0.23), meeting estimates
EARNINGS | Aug 11, 2026, 09:32 PM UTC
L
EPRX Reports Second Quarter 2026 Financial Results
Eupraxia Pharmaceuticals reports second quarter 2026 financial results
EARNINGS | Aug 11, 2026, 09:21 PM UTC
M
EPRX: Oppenheimer Initiates
Oppenheimer initiates coverage on Eupraxia Pharmaceuticals with an Outperform rating and a price target of $17
EQUITY | Jun 26, 2026, 01:12 PM UTC
M
BDC: BUY @ Citi
Citi initiates BDC with a BUY rating, among other top initiations
EQUITY | Jun 26, 2026, 11:17 AM UTC